Blinded validation cohort achieves over 95% sensitivity for stage I & II cancers with 95% specificity Capture-Seq™ Targets $36 Billion TAM in Early Cancer Detection and MRD. HENDERSON, Nev., March 25, ...
To negotiate with large multi-national companies to launch our Nu.Q® NETs test on their extensive base of installed machines already servicing every hospital in the world, with existing labs and sales ...
HENDERSON, Nev., Sept. 29, 2025 /PRNewswire/ -- VolitionRx Limited (VNRX) (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has signed an agreement with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results